Key facts
- It has raised $1.9M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Alumni Ventures, Caffeinated Capital, VentureWell, BoxOne Ventures, 1517 Fund — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Acorn Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for Acorn Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acorn Genetics
Developer of a novel third-generation automated, low-cost sequencing platform intended to make genetic testing more powerful, accessible, and cost-efficient to all. The company's services include delivering at-home genetic testing through a precise genetic sequencer, enabling clients to take action to beat diseases such as cancer, Alzheimer's, and heart disease years before they start to affect their lives.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2019
- Employees
- 5
- Website
- acorngenetics.com/
- Ownership
- Privately Held (backing)
Acorn Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acorn Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acorn Genetics in its N-PORT filings yet. We sweep new filings monthly.